Alnylam Pharmaceuticals, Inc. (ALNY)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
237.10 USD
+0.54
(0.228%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 240.00 +2.90 (1.223%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:58 a.m. EDT
Alnylam presents a compelling dichotomy: exceptional financial fundamentals versus a depressed technical setup. The company boasts a 67% revenue growth rate, nearly 100% return on equity, and a fortress balance sheet with cash exceeding debt, justifying a top-tier long-term rating despite the sector's inherent risks. However, the stock trades significantly below its 50-day and 200-day averages and is well off its 2025 anchor price, creating a short-term headwind. Options flow confirms a bullish bias, with major open interest walls at 280-300 for 2027, suggesting smart money expects a recovery toward analyst targets. The forward P/E of 18.8x offers a margin of safety compared to the trailing 41x, indicating the market has priced in near-term uncertainty. For investors, this is a high-conviction long-term hold waiting for the technicals to align. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.136319 |
| AutoETS | 0.152069 |
| AutoARIMA | 0.153341 |
| MSTL | 0.155773 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 12.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.209 |
| Excess Kurtosis | -1.29 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 220.623 |
| Revenue per Share | 36.245 |
| Market Cap | 31,726,143,488 |
| Trailing P/E | 41.16 |
| Forward P/E | 18.84 |
| Beta | 0.28 |
| Profit Margins | 16.13% |
| Website | https://www.alnylam.com |
As of Aug. 22, 2026, 4:58 a.m. EDT: Speculators are positioning for significant upside with heavy call open interest concentrated at 280-300 strikes for 2027, while maintaining defensive put positions at 200-250 strikes for near-term protection. Implied volatility skews indicate anticipation of high-beta moves, but the open interest concentration suggests a bullish bias for the medium-to-long term.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.470783 |
| Address1 | 675 West Kendall Street |
| Address2 | Henri A. Termeer Square |
| All Time High | 495.55 |
| All Time Low | 3.65 |
| Ask | 235.64 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 1,626,870 |
| Average Daily Volume3 Month | 1,734,261 |
| Average Volume | 1,734,261 |
| Average Volume10Days | 1,626,870 |
| Beta | 0.279 |
| Bid | 235.03 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 10.125 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 237.1 |
| Current Ratio | 3.055 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 238.97 |
| Day Low | 223.61 |
| Debt To Equity | 220.623 |
| Display Name | Alnylam Pharmaceuticals |
| Earnings Call Timestamp End | 1,785,414,600 |
| Earnings Call Timestamp Start | 1,785,414,600 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,793,277,000 |
| Earnings Timestamp Start | 1,793,277,000 |
| Ebitda | 1,054,537,984 |
| Ebitda Margins | 0.2195 |
| Enterprise To Ebitda | 29.781 |
| Enterprise To Revenue | 6.537 |
| Enterprise Value | 31,405,484,032 |
| Eps Current Year | 8.91542 |
| Eps Forward | 12.58719 |
| Eps Trailing Twelve Months | 5.76 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 551 8101 |
| Fifty Day Average | 262.8398 |
| Fifty Day Average Change | -25.739807 |
| Fifty Day Average Change Percent | -0.097929634 |
| Fifty Two Week Change Percent | -47.0783 |
| Fifty Two Week High | 495.55 |
| Fifty Two Week High Change | -258.44998 |
| Fifty Two Week High Change Percent | -0.5215417 |
| Fifty Two Week Low | 197.81 |
| Fifty Two Week Low Change | 39.29001 |
| Fifty Two Week Low Change Percent | 0.19862498 |
| Fifty Two Week Range | 197.81 - 495.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,086,096,600,000 |
| Float Shares | 133,236,415 |
| Forward Eps | 12.58719 |
| Forward P E | 18.836613 |
| Free Cashflow | 271,544,256 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,500 |
| Fullday Change | 0.540009 |
| Fullday Change Percent | 0.228276 |
| Fullday Price | 240.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.79654 |
| Gross Profits | 3,826,732,032 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00184 |
| Held Percent Institutions | 1.01703 |
| Implied Shares Outstanding | 133,809,118 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Alnylam Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 31,726,143,488 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_2796659 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 774,710,976 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 31,653,884,954 |
| Number Of Analyst Opinions | 26 |
| Open | 224.465 |
| Operating Cashflow | 911,812,992 |
| Operating Margins | 0.17928 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.46 |
| Phone | 617 551 8200 |
| Post Market Change | 2.899994 |
| Post Market Change Percent | 1.22311 |
| Post Market Price | 240.0 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 236.56 |
| Price Eps Current Year | 26.594374 |
| Price Hint | 2 |
| Price To Book | 23.417284 |
| Price To Sales Trailing12 Months | 6.6038594 |
| Profit Margins | 0.16126 |
| Quick Ratio | 2.791 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.67857 |
| Region | US |
| Regular Market Change | 0.540009 |
| Regular Market Change Percent | 0.228276 |
| Regular Market Day High | 239.02 |
| Regular Market Day Low | 223.61 |
| Regular Market Day Range | 223.61 - 239.02 |
| Regular Market Open | 224.465 |
| Regular Market Previous Close | 236.56 |
| Regular Market Price | 237.1 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,835,489 |
| Return On Assets | 0.123430006 |
| Return On Equity | 0.96555 |
| Revenue Growth | 0.669 |
| Revenue Per Share | 36.245 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 133,809,118 |
| Shares Percent Shares Out | 0.0357 |
| Shares Short | 4,770,978 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,773,373 |
| Short Name | Alnylam Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0475 |
| Short Ratio | 2.29 |
| Source Interval | 15 |
| State | MA |
| Symbol | ALNY |
| Target High Price | 536.0 |
| Target Low Price | 230.0 |
| Target Mean Price | 370.2 |
| Target Median Price | 350.0 |
| Total Cash | 3,308,146,944 |
| Total Cash Per Share | 24.723 |
| Total Debt | 2,987,489,024 |
| Total Revenue | 4,804,182,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 5.76 |
| Trailing P E | 41.163193 |
| Trailing Peg Ratio | 0.4494 |
| Triggerable | 1 |
| Two Hundred Day Average | 327.0772 |
| Two Hundred Day Average Change | -89.9772 |
| Two Hundred Day Average Change Percent | -0.2750947 |
| Type Disp | Equity |
| Volume | 1,835,489 |
| Website | https://www.alnylam.com |
| Zip | 2,142 |